{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T05:45:19Z","timestamp":1794894319326,"version":"4.9.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,5,14]],"date-time":"2018-05-14T00:00:00Z","timestamp":1526256000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,5,14]],"date-time":"2018-05-14T00:00:00Z","timestamp":1526256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Metastatic uveal melanoma is a deadly disease with no proven standard of care. Here we present a metastatic uveal melanoma patient with an exceptional high sensitivity to a PD-1 inhibitor associated with outlier CpG&gt;TpG mutation burden,\n                    <jats:italic>MBD4<\/jats:italic>\n                    germline deleterious mutation, and somatic\n                    <jats:italic>MBD4<\/jats:italic>\n                    inactivation in the tumor. We identify additional tumors in The Cancer Genome Atlas (TCGA) cohorts with similar hypermutator profiles in patients carrying germline deleterious\n                    <jats:italic>MBD4<\/jats:italic>\n                    mutations and somatic loss of heterozygosity. This\n                    <jats:italic>MBD4<\/jats:italic>\n                    -related hypermutator phenotype may explain unexpected responses to immune checkpoint inhibitors.\n                  <\/jats:p>","DOI":"10.1038\/s41467-018-04322-5","type":"journal-article","created":{"date-parts":[[2018,5,8]],"date-time":"2018-05-08T05:32:36Z","timestamp":1525757556000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":147,"title":["Outlier response to anti-PD1 in uveal melanoma reveals germline MBD4 mutations in hypermutated tumors"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5443-0802","authenticated-orcid":false,"given":"Manuel","family":"Rodrigues","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenha","family":"Mobuchon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Houy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Fi\u00e9vet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Gardrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond L.","family":"Barnhill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Popova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Servois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurore","family":"Rampanou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurore","family":"Mouton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Dayot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Raynal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mich\u00e8le","family":"Galut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3385-7831","authenticated-orcid":false,"given":"Marc","family":"Putterman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Tick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Cassoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Roman-Roman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois-Cl\u00e9ment","family":"Bidard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3161-7719","authenticated-orcid":false,"given":"Olivier","family":"Lantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Mariani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Piperno-Neumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8100-2272","authenticated-orcid":false,"given":"Marc-Henri","family":"Stern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,14]]},"reference":[{"key":"4322_CR1","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1158\/2159-8290.CD-13-0330","volume":"3","author":"SJ Furney","year":"2013","unstructured":"Furney, S. J. et al. SF3B1 mutations are associated with alternative splicing in uveal melanoma. Cancer Discov. 3, 1122\u20131129 (2013).","journal-title":"Cancer Discov."},{"key":"4322_CR2","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.ccell.2017.07.003","volume":"32","author":"AG Robertson","year":"2017","unstructured":"Robertson, A. G. et al. Integrative analysis identifies four molecular and clinical subsets in uveal melanoma. Cancer Cell 32, 204\u2013220.e15 (2017).","journal-title":"Cancer Cell"},{"key":"4322_CR3","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1136\/bjophthalmol-2016-309034","volume":"101","author":"RD Carvajal","year":"2017","unstructured":"Carvajal, R. D. et al. Metastatic disease from uveal melanoma: treatment options and future prospects. Br. J. Ophthalmol. 101, 38\u201344 (2017).","journal-title":"Br. J. Ophthalmol."},{"key":"4322_CR4","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/nature08802","volume":"464","author":"Y He","year":"2010","unstructured":"He, Y. et al. Heteroplasmic mitochondrial DNA mutations in normal and tumour cells. Nature 464, 610\u2013614 (2010).","journal-title":"Nature"},{"key":"4322_CR5","doi-asserted-by":"publisher","first-page":"3344","DOI":"10.1002\/cncr.30258","volume":"122","author":"AP Algazi","year":"2016","unstructured":"Algazi, A. P. et al. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer 122, 3344\u20133353 (2016).","journal-title":"Cancer"},{"key":"4322_CR6","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1097\/CMR.0000000000000242","volume":"26","author":"LA Kottschade","year":"2016","unstructured":"Kottschade, L. A. et al. The use of pembrolizumab for the treatment of metastatic uveal melanoma. Melanoma Res. 26, 300\u2013303 (2016).","journal-title":"Melanoma Res."},{"key":"4322_CR7","doi-asserted-by":"publisher","first-page":"e1143997","DOI":"10.1080\/2162402X.2016.1143997","volume":"5","author":"I Karydis","year":"2016","unstructured":"Karydis, I. et al. Clinical activity and safety of pembrolizumab in ipilimumab pre-treated patients with uveal melanoma. Oncoimmunology 5, e1143997 (2016).","journal-title":"Oncoimmunology"},{"key":"4322_CR8","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1126\/science.aad0095","volume":"350","author":"EM Van Allen","year":"2015","unstructured":"Van Allen, E. M. et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350, 207\u2013211 (2015).","journal-title":"Science"},{"key":"4322_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10615","volume":"7","author":"S Alsafadi","year":"2016","unstructured":"Alsafadi, S. et al. Cancer-associated SF3B1 mutations affect alternative splicing by promoting alternative branchpoint usage. Nat. Commun. 7, 10615 (2016).","journal-title":"Nat. Commun."},{"key":"4322_CR10","doi-asserted-by":"publisher","first-page":"3934","DOI":"10.1158\/1078-0432.CCR-12-0309","volume":"18","author":"J Madic","year":"2012","unstructured":"Madic, J. et al. Pyrophosphorolysis-activated polymerization detects circulating tumor DNA in metastatic uveal melanoma. Clin. Cancer Res. 18, 3934\u20133941 (2012).","journal-title":"Clin. Cancer Res."},{"key":"4322_CR11","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1126\/science.1243211","volume":"343","author":"L Costantino","year":"2014","unstructured":"Costantino, L. et al. Break-induced replication repair of damaged forks induces genomic duplications in human cells. Science 343, 88\u201391 (2014).","journal-title":"Science"},{"key":"4322_CR12","doi-asserted-by":"publisher","first-page":"5399","DOI":"10.1093\/nar\/gkg730","volume":"31","author":"JH Yoon","year":"2003","unstructured":"Yoon, J. H., Iwai, S., O\u2019Connor, T. R. & Pfeifer, G. P. Human thymine DNA glycosylase (TDG) and methyl-CpG-binding protein 4 (MBD4) excise thymine glycol (Tg) from a Tg:G mispair. Nucleic Acids Res. 31, 5399\u20135404 (2003).","journal-title":"Nucleic Acids Res."},{"key":"4322_CR13","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/45843","volume":"401","author":"B Hendrich","year":"1999","unstructured":"Hendrich, B., Hardeland, U., Ng, H. H., Jiricny, J. & Bird, A. The thymine glycosylase MBD4 can bind to the product of deamination at methylated CpG sites. Nature 401, 301\u2013304 (1999).","journal-title":"Nature"},{"key":"4322_CR14","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1158\/2159-8290.CD-15-0344","volume":"5","author":"C Swanton","year":"2015","unstructured":"Swanton, C., McGranahan, N., Starrett, G. J. & Harris, R. S. APOBEC enzymes: mutagenic fuel for cancer evolution and heterogeneity. Cancer Discov. 5, 704\u2013712 (2015).","journal-title":"Cancer Discov."},{"key":"4322_CR15","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.2147\/OPTH.S113623","volume":"10","author":"K Mahendraraj","year":"2016","unstructured":"Mahendraraj, K., Lau, C. S., Lee, I. & Chamberlain, R. S. Trends in incidence, survival, and management of uveal melanoma: a population-based study of 7,516 patients from the Surveillance, Epidemiology, and End Results database (1973\u20132012). Clin. Ophthalmol. 10, 2113\u20132119 (2016).","journal-title":"Clin. Ophthalmol."},{"key":"4322_CR16","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1158\/1055-9965.EPI-14-0275","volume":"23","author":"JP Thakkar","year":"2014","unstructured":"Thakkar, J. P. et al. Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol. Biomarkers Prev. 23, 1985\u20131996 (2014).","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"4322_CR17","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1126\/science.1073354","volume":"297","author":"CB Millar","year":"2002","unstructured":"Millar, C. B. et al. Enhanced CpG mutability and tumorigenesis in MBD4-deficient mice. Science 297, 403\u2013405 (2002).","journal-title":"Science"},{"key":"4322_CR18","doi-asserted-by":"publisher","first-page":"6899","DOI":"10.1073\/pnas.84.19.6899","volume":"84","author":"AJ Wong","year":"1987","unstructured":"Wong, A. J. et al. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc. Natl Acad. Sci. USA 84, 6899\u20136903 (1987).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"4322_CR19","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi, N. A. et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124\u2013128 (2015).","journal-title":"Science"},{"key":"4322_CR20","first-page":"90","volume":"12","author":"SM Ginolhac","year":"2003","unstructured":"Ginolhac, S. M. et al. BRCA1 wild-type allele modifies risk of ovarian cancer in carriers of BRCA1 germ-line mutations. Cancer Epidemiol. Biomarkers Prev. 12, 90\u201395 (2003).","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"4322_CR21","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nmeth.1923","volume":"9","author":"B Langmead","year":"2012","unstructured":"Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357\u2013359 (2012).","journal-title":"Nat. Methods"},{"key":"4322_CR22","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/mgg3.42","volume":"2","author":"F Lescai","year":"2014","unstructured":"Lescai, F. et al. Identification and validation of loss of function variants in clinical contexts. Mol. Genet. Genomic. Med. 2, 58\u201363 (2014).","journal-title":"Mol. Genet. Genomic. Med."},{"key":"4322_CR23","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nbt.2514","volume":"31","author":"K Cibulskis","year":"2013","unstructured":"Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213\u2013219 (2013).","journal-title":"Nat. Biotechnol."},{"key":"4322_CR24","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1126\/science.1905840","volume":"253","author":"M Hollstein","year":"1991","unstructured":"Hollstein, M., Sidransky, D., Vogelstein, B. & Harris, C. C. p53 mutations in human cancers. Science 253, 49\u201353 (1991).","journal-title":"Science"},{"key":"4322_CR25","doi-asserted-by":"publisher","first-page":"e1000294","DOI":"10.1371\/journal.pbio.1000294","volume":"8","author":"SP Dickson","year":"2010","unstructured":"Dickson, S. P., Wang, K., Krantz, I., Hakonarson, H. & Goldstein, D. B. Rare variants create synthetic genome-wide associations. PLoS Biol. 8, e1000294 (2010).","journal-title":"PLoS Biol."},{"key":"4322_CR26","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1101\/gr.9.8.677","volume":"9","author":"ST Sherry","year":"1999","unstructured":"Sherry, S. T., Ward, M. & Sirotkin, K. dbSNP-database for single nucleotide polymorphisms and other classes of minor genetic variation. Genome Res. 9, 677\u2013679 (1999).","journal-title":"Genome Res."},{"key":"4322_CR27","doi-asserted-by":"publisher","first-page":"D805","DOI":"10.1093\/nar\/gku1075","volume":"43","author":"SA Forbes","year":"2015","unstructured":"Forbes, S. A. et al. COSMIC: exploring the world\u2019s knowledge of somatic mutations in human cancer. Nucleic Acids Res. 43, D805\u2013D811 (2015).","journal-title":"Nucleic Acids Res."},{"key":"4322_CR28","doi-asserted-by":"publisher","first-page":"e1003212","DOI":"10.1371\/journal.pgen.1003212","volume":"9","author":"FJ Couch","year":"2013","unstructured":"Couch, F. J. et al. Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet. 9, e1003212 (2013).","journal-title":"PLoS Genet."},{"key":"4322_CR29","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1158\/1078-0432.CCR-15-2294","volume":"22","author":"LD Rothermel","year":"2016","unstructured":"Rothermel, L. D. et al. Identification of an immunogenic subset of metastatic uveal melanoma. Clin. Cancer Res. 22, 2237\u20132249 (2016).","journal-title":"Clin. Cancer Res."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-04322-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-04322-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-04322-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T08:57:47Z","timestamp":1671526667000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-04322-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,14]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["4322"],"URL":"https:\/\/doi.org\/10.1038\/s41467-018-04322-5","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,14]]},"assertion":[{"value":"24 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.R. and S.P.-N. received research grants from Bristol-Myers Squibb and Merck Sharp & Dohme; R.L.B. received the technical support from Merck Sharp & Dohme for IHC. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1866"}}